19 February 2018
News and Views
Links and Services
The latest issue of the Alimentary Pharmacology & Therapeutics evaluates long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Octreotide LAR is an established treatment for malignant carcinoid syndrome.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors